← Back to Patent Explorer
US4014989A Expired / Lapsed US ⏱️ 0.0 years remaining

Pharmaceutical aerosol compositions comprising putrescine prostaglandins

Assignee: Alza Corp
•
Filing: 1975-10-01
•
Granted: 1977-03-29
•
Expires: 1995-10-01
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Novel compounds of the formulae: ##STR1## wherein R 2 and R 6 are hydrogen when Z 2 is a single bond and when Z 2 is a double bond R 2 and R 6 are absent; R 3 is a keto, ##STR2## R 7 is OH or OR 9 ; R 8 is H or OH; R 9 is acyl or alkoxyalkyl; R 10 is H or ##STR3## Z 1 is --CH 2 CH 2 -- or cis --CH=CH--; Z 2 is a single bond or a double bond; Z 3 is a single bond or a double bond when R 4 and R 5 are hydrogen; Z 4 is --CH 2 CH 2 -- or trans --CH=CH--; Z 5 is --CH 2 CH 2 -- or cis --CH=CH--; n is 2 to 5, m is 1 to 3, and x is 1 to 2. The compounds are useful for regulating blood pressure, for stimulating smooth muscles, for inhibiting gastric secretion and inhibiting platelet aggregation and they possess improved biological stability and enhanced membrane permeability to serve as an in vivo reservoir of the prostaglandin to ensure the biological availability of the prostaglandin.

Inventors

  • 👤 Alejandro Zaffaroni

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-26 17:06
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/007; A61K9/0073; C; C07; C07C; C07C405/00

Claims Analysis

Total Claims: 2
Claim 1
Independent Claim 55 words
A pharmaceutical aerosol formation for inhalation therapy wherein the aerosol is comprised of about 100 mg to 500 mg of a prostonate selected from the group consisting of 1,4-diaminobutane-11α,15(S)-dihydroxy-9-oxo-5-cis,13-trans-prostadienoate; 15(S)-hydroxy-9-oxo-10,13-trans-prostadienoate; 9α,11α,15(S)-trihydroxy-5-cis,13-trans-prostadienoate; and 9α,11α,15(S)-trihydroxy-5-cis,13-trans,17-cis-prostatrienoate wherein the prostonate is mixed with an inert non-toxic gaseous propellant and a pharmaceutically acceptable cosolvent for the propellant and the prostonate.
Claim 2
Dependent Claim 55 words
A pharmaceutical aerosol formation for inhalation therapy wherein the aerosol is comprised of about 100 mg to 500 mg of a prostonate selected from the group consisting of 1,4-diaminobutane-11α,15(S)-dihydroxy-9-oxo-5-cis,13-trans-prostadienoate; 15(S)-hydroxy-9-oxo-10,13-trans-prostadienoate; 9α,11α,15(S)-trihydroxy-5-cis,13-trans-prostadienoate; and 9α,11α,15(S)-trihydroxy-5-cis,13-trans,17-cis-prostatrienoate wherein the prostonate is mixed with an inert non-toxic gaseous propellant and a pharmaceutically acceptable cosolvent for the propellant and the prostonate.

References Cited (Backward Citations)

BE481036A Cited
US2165470A Cited
GB851827A Cited
GB1040544A Cited
US3271248A Cited
GB1120243A Cited
US3764620A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1980-03-28 1980-09-27 1981-03-29 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1984-03-28 1984-09-27 1985-03-29 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1988-03-28 1988-09-27 1989-03-29 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag